ZA200201383B - Composition for IVF. - Google Patents
Composition for IVF. Download PDFInfo
- Publication number
- ZA200201383B ZA200201383B ZA200201383A ZA200201383A ZA200201383B ZA 200201383 B ZA200201383 B ZA 200201383B ZA 200201383 A ZA200201383 A ZA 200201383A ZA 200201383 A ZA200201383 A ZA 200201383A ZA 200201383 B ZA200201383 B ZA 200201383B
- Authority
- ZA
- South Africa
- Prior art keywords
- mas
- composition
- weight
- preferred
- content
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 40
- 239000000243 solution Substances 0.000 claims description 40
- LFQXEZVYNCBVDO-PBJLWWPKSA-N 4,4-dimethyl-5alpha-cholesta-8,14,24-trien-3beta-ol Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CCC1=C2CC[C@]2(C)[C@@H]([C@@H](CCC=C(C)C)C)CC=C21 LFQXEZVYNCBVDO-PBJLWWPKSA-N 0.000 claims description 33
- 210000000287 oocyte Anatomy 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000000654 additive Substances 0.000 claims description 10
- 230000000996 additive effect Effects 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 8
- 239000003960 organic solvent Substances 0.000 claims description 5
- 239000012265 solid product Substances 0.000 claims description 3
- 230000015556 catabolic process Effects 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 150000001408 amides Chemical class 0.000 claims 1
- 229930182817 methionine Natural products 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 34
- 108091006905 Human Serum Albumin Proteins 0.000 description 24
- 102000008100 Human Serum Albumin Human genes 0.000 description 24
- 239000002609 medium Substances 0.000 description 12
- 239000000047 product Substances 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 239000007758 minimum essential medium Substances 0.000 description 6
- 239000011550 stock solution Substances 0.000 description 6
- 239000012736 aqueous medium Substances 0.000 description 5
- 230000008020 evaporation Effects 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000003744 In vitro fertilisation Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000021121 meiosis Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000012384 transportation and delivery Methods 0.000 description 2
- MCKLJFJEQRYRQT-YGDKQAQQSA-N (8s,9s,10r,13s,14s,17s)-17-[(2s)-2-hydroxy-6-methylheptan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-ol Chemical compound C1C=C2CC(O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@](C)(O)CCCC(C)C)[C@@]1(C)CC2 MCKLJFJEQRYRQT-YGDKQAQQSA-N 0.000 description 1
- WQTCTMDKQPZJES-UHFFFAOYSA-N 2-aminoethyl dihydrogen phosphate;nonane Chemical compound NCCOP(O)(O)=O.CCCCCCCCC.CCCCCCCCC WQTCTMDKQPZJES-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000011767 DBA/2J (JAX™ mouse strain) Methods 0.000 description 1
- 208000034423 Delivery Diseases 0.000 description 1
- 101100536354 Drosophila melanogaster tant gene Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 108010006578 follitropin alfa Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 229940094892 gonadotropins Drugs 0.000 description 1
- 229940057854 gonal f Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 239000002342 ribonucleoside Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/81—Packaged device or kit
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA199901308 | 1999-09-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200201383B true ZA200201383B (en) | 2002-11-27 |
Family
ID=8103409
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200201383A ZA200201383B (en) | 1999-09-16 | 2002-02-19 | Composition for IVF. |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US6844313B1 (fr) |
| EP (1) | EP1216059B1 (fr) |
| JP (1) | JP2003509365A (fr) |
| KR (1) | KR100757909B1 (fr) |
| CN (1) | CN1222319C (fr) |
| AT (1) | ATE306942T1 (fr) |
| AU (1) | AU781994B2 (fr) |
| BR (1) | BR0014058A (fr) |
| CA (1) | CA2382908A1 (fr) |
| CZ (1) | CZ2002591A3 (fr) |
| DE (1) | DE60023324T2 (fr) |
| ES (1) | ES2252048T3 (fr) |
| HU (1) | HUP0202630A3 (fr) |
| IL (1) | IL148234A0 (fr) |
| MX (1) | MXPA02002439A (fr) |
| NO (1) | NO323694B1 (fr) |
| PL (1) | PL202224B1 (fr) |
| RU (1) | RU2263516C2 (fr) |
| UA (1) | UA78183C2 (fr) |
| WO (1) | WO2001019354A2 (fr) |
| ZA (1) | ZA200201383B (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL144529A0 (en) * | 1999-02-26 | 2002-05-23 | Novo Nordisk As | Meiosis activating sterol augments implantation rate |
| KR100757909B1 (ko) | 1999-09-16 | 2007-09-11 | 노보 노르디스크 에이/에스 | Ｉｖｆ를 위한 조성물 |
| MXPA02007818A (es) * | 2000-02-25 | 2002-10-23 | Schering Ag | Tasa de implantacion mejorada utilizando ff-mas. |
| US6988613B2 (en) | 2001-02-06 | 2006-01-24 | Novo Nordisk A/S | Composition for IVF |
| EP1245572A1 (fr) | 2001-03-26 | 2002-10-02 | Schering Aktiengesellschaft | Composés aminostérols, leur utilisation pour la préparation des médicaments pour la régulation de la méiose et un procédé de leur préparation |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4175074A (en) | 1976-08-23 | 1979-11-20 | Deshmukh Arvind D | Serum-soluble cholesterol compounds and method for their preparation |
| US4751219A (en) | 1985-02-05 | 1988-06-14 | Nederlandse Centrale Organisatie Voor Toegepast-Natuur-Wetenschappelijk Onderzoek | Synthetic glycolipides, a process for the preparation thereof and several uses for these synthetic glycolipides |
| AU4312489A (en) * | 1988-09-23 | 1990-04-18 | Cetus Corporation | Lipid microemulsions for culture media |
| DE4221880A1 (de) | 1992-07-03 | 1994-01-05 | Alfatec Pharma Gmbh | Feste und flüssige Lösungen von schwer wasserlöslichen Arzneistoffen |
| WO1994012158A1 (fr) * | 1992-12-02 | 1994-06-09 | Alkermes Controlled Therapeutics, Inc. | Microspheres contenant une hormone de croissance a liberation regulee |
| US5716777A (en) * | 1994-06-23 | 1998-02-10 | Novo Nordisk A/S | Regulation of meiosis using sterols |
| US6281015B1 (en) * | 1994-12-16 | 2001-08-28 | Children's Medical Center Corp. | Localized delivery of factors enhancing survival of transplanted cells |
| CZ279797A3 (cs) | 1995-03-06 | 1998-01-14 | Novo Nordisk A/S | Způsob stimulace miózy zárodečné buňky a použití sloučeniny, která způsobuje akumulaci látky aktivující endogenní miózu |
| CN1191543A (zh) | 1995-06-23 | 1998-08-26 | 诺沃挪第克公司 | 减数分裂调控化合物 |
| GB9625175D0 (en) * | 1996-12-04 | 1997-01-22 | Medi Cult As | Serum-free cell culture media |
| EP0946584B1 (fr) * | 1996-12-20 | 2003-04-23 | Novo Nordisk A/S | Composés regulateurs de meiose |
| EP0988312B1 (fr) | 1997-06-04 | 2002-04-03 | Akzo Nobel N.V. | Derives de 17beta-allyloxy(thio)alkyl-androstane destines a une modulation de meiose |
| HUP9701554D0 (en) | 1997-09-18 | 1997-11-28 | Human Oltoanyagtermeloe Gyogys | Pharmaceutical composition containing plazma proteins |
| KR20010043828A (ko) | 1998-05-26 | 2001-05-25 | 에바-마리아 시마-메이어, 얼설라 멜져, 마거, 하르트만 | ｃＡＭＰ-증강 화합물 단독 또는 감수분열-자극 화합물하나 이상과의 조합에 의한 불임 치료 방법 |
| IL144529A0 (en) * | 1999-02-26 | 2002-05-23 | Novo Nordisk As | Meiosis activating sterol augments implantation rate |
| KR100757909B1 (ko) | 1999-09-16 | 2007-09-11 | 노보 노르디스크 에이/에스 | Ｉｖｆ를 위한 조성물 |
-
2000
- 2000-09-11 KR KR1020027003526A patent/KR100757909B1/ko not_active IP Right Cessation
- 2000-09-11 HU HU0202630A patent/HUP0202630A3/hu unknown
- 2000-09-11 CA CA002382908A patent/CA2382908A1/fr not_active Abandoned
- 2000-09-11 BR BR0014058-9A patent/BR0014058A/pt not_active Application Discontinuation
- 2000-09-11 RU RU2002109794/15A patent/RU2263516C2/ru not_active IP Right Cessation
- 2000-09-11 CN CNB008128820A patent/CN1222319C/zh not_active Expired - Fee Related
- 2000-09-11 WO PCT/DK2000/000500 patent/WO2001019354A2/fr active IP Right Grant
- 2000-09-11 AT AT00958274T patent/ATE306942T1/de not_active IP Right Cessation
- 2000-09-11 EP EP00958274A patent/EP1216059B1/fr not_active Expired - Lifetime
- 2000-09-11 ES ES00958274T patent/ES2252048T3/es not_active Expired - Lifetime
- 2000-09-11 CZ CZ2002591A patent/CZ2002591A3/cs unknown
- 2000-09-11 AU AU69850/00A patent/AU781994B2/en not_active Ceased
- 2000-09-11 IL IL14823400A patent/IL148234A0/xx unknown
- 2000-09-11 JP JP2001522989A patent/JP2003509365A/ja active Pending
- 2000-09-11 DE DE60023324T patent/DE60023324T2/de not_active Expired - Fee Related
- 2000-09-11 MX MXPA02002439A patent/MXPA02002439A/es active IP Right Grant
- 2000-09-11 PL PL353968A patent/PL202224B1/pl not_active IP Right Cessation
- 2000-09-14 US US09/661,696 patent/US6844313B1/en not_active Expired - Fee Related
- 2000-11-09 UA UA2002032077A patent/UA78183C2/uk unknown
-
2002
- 2002-02-19 ZA ZA200201383A patent/ZA200201383B/en unknown
- 2002-03-15 NO NO20021309A patent/NO323694B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20021309L (no) | 2002-03-15 |
| DE60023324D1 (de) | 2005-11-24 |
| PL353968A1 (en) | 2003-12-15 |
| KR20020032593A (ko) | 2002-05-03 |
| RU2263516C2 (ru) | 2005-11-10 |
| ES2252048T3 (es) | 2006-05-16 |
| NO323694B1 (no) | 2007-06-25 |
| IL148234A0 (en) | 2002-09-12 |
| BR0014058A (pt) | 2004-03-30 |
| AU6985000A (en) | 2001-04-17 |
| US6844313B1 (en) | 2005-01-18 |
| CN1373675A (zh) | 2002-10-09 |
| HUP0202630A3 (en) | 2004-06-28 |
| UA78183C2 (en) | 2007-03-15 |
| CA2382908A1 (fr) | 2001-03-22 |
| DE60023324T2 (de) | 2006-07-20 |
| MXPA02002439A (es) | 2002-07-30 |
| JP2003509365A (ja) | 2003-03-11 |
| CN1222319C (zh) | 2005-10-12 |
| AU781994B2 (en) | 2005-06-23 |
| ATE306942T1 (de) | 2005-11-15 |
| NO20021309D0 (no) | 2002-03-15 |
| EP1216059A2 (fr) | 2002-06-26 |
| PL202224B1 (pl) | 2009-06-30 |
| WO2001019354A3 (fr) | 2001-06-14 |
| KR100757909B1 (ko) | 2007-09-11 |
| WO2001019354A2 (fr) | 2001-03-22 |
| CZ2002591A3 (cs) | 2002-08-14 |
| EP1216059B1 (fr) | 2005-10-19 |
| HUP0202630A2 (hu) | 2002-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1326817C (fr) | Facteur favorisant la guerison des menisques | |
| EP0509761B1 (fr) | Composition transdermique à base de sélégiline | |
| US5637309A (en) | Physiologically active substance-prolonged releasing-type pharmaceutical preparation | |
| EP0420649A2 (fr) | Formulations aqueuses stabilisées à base de petits peptides | |
| EP0869816B1 (fr) | Compositions seches comprenant des stabilisateurs hydrophobes | |
| BG61267B1 (en) | Growth hormone crystals and method for production thereof | |
| AU2012288422B2 (en) | Matrix compositions for controlled release of peptide and polypeptide molecules | |
| AU2012288422A1 (en) | Matrix compositions for controlled release of peptide and polypeptide molecules | |
| AU781994B2 (en) | Composition for IVF | |
| US5140010A (en) | Stabilized aqueous formulations of thymopentin | |
| EP2833891B1 (fr) | Composition pour le traitement de la fibrose kystique et de l'induction de la sécrétion d'ions | |
| US6988613B2 (en) | Composition for IVF | |
| EP1359881A1 (fr) | Procede et contenant a faible teneur en oxygene et renfermant des substances activant la meiose | |
| EP0274219A2 (fr) | Composition de liposome contenant de l'interleukine-2 et méthode de sa fabrication | |
| JPH0733667A (ja) | ４，６−ｏ−ヒドロキシホスホリルグルコサミン誘導体の水溶液及び水溶化方法 | |
| Chan Philip et al. | Calmodulin level changes associated with cyclic AMP treatment in cultured squirrel monkey oocytes and sperm. |